短链脂肪酸在非酒精性脂肪性肝病和胰岛素抵抗中的作用及进展

摘要/Abstract

摘要： 肠道微生物发酵产生的短链脂肪酸不仅在肠道健康中发挥重要作用,并且能够进入体循环直接影响宿主的代谢与功能。非酒精性脂肪性肝病与2型糖尿病密切相关,胰岛素抵抗为二者的共同发病机制。本文以短链脂肪酸对胰岛素抵抗的影响为着重点,探讨短链脂肪酸作为代谢靶点在非酒精性脂肪性肝病和胰岛素抵抗预防和治疗中的潜在临床价值。

关键词: 非酒精性脂肪性肝病, 短链脂肪酸, 胰岛素抵抗, 肠道菌群, 糖尿病

屠晓婷, 卜淑蕊. 短链脂肪酸在非酒精性脂肪性肝病和胰岛素抵抗中的作用及进展[J]. 肝脏, 2023, 28(12): 1521-1524.

[1] Wong VW, Wong GL, Chan RS, et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol, 2018, 69(6): 1349-1356.
[2] Ching-Yeung Yu B, Kwok D, Wong VW. Magnitude of nonalcoholic fatty liver disease: eastern perspective. J Clin Exp Hepatol, 2019, 9(4): 491-496.
[3] Portincasa P, Bonfrate L, Vacca M, et al. Gut microbiota and short chain fatty acids: implications in glucose homeostasis. Int J Mol Sci, 2022, 23(3):1105.
[4] Eslam M, Sanyal A J, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 2020, 158(7): 1999-2014.e1991.
[5] Loomba R, Abraham M, Unalp A, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology, 2012, 56(3): 943-951.
[6] Rau M, Rehman A, Dittrich M, et al. Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease. United European Gastroenterol J, 2018, 6(10): 1496-1507.
[7] Tang C, Ahmed K, Gille A, et al. Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes. Nat Med, 2015, 21(2): 173-177.
[8] Priyadarshini M, Villa SR, Fuller M, et al. An acetate-specific GPCR, FFAR2, regulates insulin secretion. Mol Endocrinol, 2015, 29(7): 1055-1066.
[9] He J, Zhang P, Shen L, et al. Short-chain fatty acids and their association with signalling pathways in inflammation, glucose and lipid metabolism. Int J Mol Sci, 2020, 21(17):6356.
[10] Sharpton SR, Ajmera V, Loomba R. Emerging role of the gut microbiome in nonalcoholic fatty liver disease: from composition to function. Clin Gastroenterol Hepatol, 2019, 17(2): 296-306.
[11] Kolodziejczyk AA, Zheng D, Shibolet O, et al. The role of the microbiome in NAFLD and NASH. EMBO Mol Med, 2019, 11(2):e9302.
[12] Chu H, Duan Y, Yang L, et al. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut, 2019, 68(2): 359-370.
[13] Luther J, Garber JJ, Khalili H, et al. Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability. Cell Mol Gastroenterol Hepatol, 2015, 1(2): 222-232.
[14] Mouries J, Brescia P, Silvestri A, et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol, 2019, 71(6): 1216-1228.
[15] Feng Y, Wang Y, Wang P, et al. Short-chain fatty acids manifest stimulative and protective effects on intestinal barrier function through the inhibition of NLRP3 inflammasome and autophagy. Cell Physiol Biochem, 2018, 49(1): 190-205.
[16] Miao W, Wu X, Wang K, et al. Sodium Butyrate Promotes Reassembly of Tight Junctions in Caco-2 Monolayers Involving Inhibition of MLCK/MLC2 Pathway and Phosphorylation of PKCβ2. Int J Mol Sci, 2016, 17(10).
[17] Zheng L, Kelly CJ, Battista KD, et al. Microbial-derived butyrate promotes epithelial barrier function through IL-10 receptor-dependent repression of claudin-2. J Immunol, 2017, 199(8): 2976-2984.
[18] Kelly CJ, Zheng L, Campbell EL, et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe, 2015, 17(5): 662-671.
[19] Aron-Wisnewsky J, Vigliotti C, Witjes J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol, 2020, 17(5): 279-297.
[20] Chambers ES, Viardot A, Psichas A, et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut, 2015, 64(11): 1744-1754.
[21] Psichas A, Sleeth ML, Murphy KG, et al. The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. Int J Obes (Lond), 2015, 39(3): 424-429.
[22] Weitkunat K, Schumann S, Nickel D, et al. Importance of propionate for the repression of hepatic lipogenesis and improvement of insulin sensitivity in high-fat diet-induced obesity. Mol Nutr Food Res, 2016, 60(12): 2611-2621.
[23] Meng Q, Duan XP, Wang CY, et al. Alisol B 23-acetate protects against non-alcoholic steatohepatitis in mice via farnesoid X receptor activation. Acta Pharmacol Sin, 2017, 38(1): 69-79.
[24] McNabney SM, Henagan TM. Short chain fatty acids in the colon and peripheral tissues: a focus on butyrate, colon cancer, obesity and insulin resistance. Nutrients, 2017, 9(12):1348.
[25] Chen YM, Liu Y, Zhou RF, et al. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci Rep, 2016, 6: 19076.
[26] Nighot M, Al-Sadi R, Guo S, et al. Lipopolysaccharide-induced increase in intestinal epithelial tight permeability is mediated by toll-like receptor 4/myeloid differentiation primary response 88 (MyD88) activation of myosin light chain kinase expression. Am J Pathol, 2017, 187(12): 2698-2710.
[27] Sun M, Wu W, Liu Z, et al. Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases. J Gastroenterol, 2017, 52(1): 1-8.
[28] Luu M, Pautz S, Kohl V, et al. The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes. Nat Commun, 2019, 10(1): 760.
[29] Zhou D, Pan Q, Xin FZ, et al. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier. World J Gastroenterol, 2017, 23(1): 60-75.
[30] Sun Q, Ji YC, Wang ZL, et al. Sodium butyrate alleviates intestinal inflammation in mice with necrotizing enterocolitis. Mediators Inflamm, 2021, 2021: 6259381.
[31] Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic steatohepatitis: a review. Jama, 2020, 323(12): 1175-1183.
[32] McNelis JC, Lee YS, Mayoral R, et al. GPR43 Potentiates β-Cell Function in Obesity. Diabetes, 2015, 64(9): 3203-3217.
[33] Saad MJ, Santos A, Prada PO. Linking gut microbiota and inflammation to obesity and insulin resistance. physiology (bethesda), 2016, 31(4): 283-293.
[34] Mazibuko SE, Muller CJ, Joubert E, et al. Amelioration of palmitate-induced insulin resistance in C₂C₁₂ muscle cells by rooibos (Aspalathus linearis). Phytomedicine, 2013, 20(10): 813-819.
[35] Keenan MJ, Zhou J, Hegsted M, et al. Role of resistant starch in improving gut health, adiposity, and insulin resistance. Adv Nutr, 2015, 6(2): 198-205.
[36] Ahn SB, Jun DW, Kang BK, et al. Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease. Sci Rep, 2019, 9(1): 5688.
[37] Bahmani F, Tajadadi-Ebrahimi M, Kolahdooz F, et al. The consumption of synbiotic bread containing lactobacillus sporogenes and inulin affects nitric oxide and malondialdehyde in patients with type 2 diabetes mellitus: randomized, double-blind, placebo-controlled trial. J Am Coll Nutr, 2016, 35(6): 506-513.
[38] Kootte RS, Levin E, Salojörvi J, et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab, 2017, 26(4): 611-619.e616.
[39] Allegretti JR, Kassam Z, Mullish BH, et al. Effects of fecal microbiota transplantation with oral capsules in obese patients. Clin Gastroenterol Hepatol, 2020, 18(4): 855-863.e852.
[40] de Groot P, Scheithauer T, Bakker GJ, et al. Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time. Gut, 2020, 69(3): 502-512.
[41] Zhou D, Pan Q, Shen F, et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep, 2017, 7(1): 1529.

短链脂肪酸在非酒精性脂肪性肝病和胰岛素抵抗中的作用及进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	邢翔宇, 牛俊奇. 代谢相关脂肪性肝病药物研发进展[J]. 肝脏, 2024, 29(1): 5-9.
[2]	赵东志, 李国东, 常媛媛, 曹哲丽, 赵雅娟. 非酒精性脂肪性肝病患者C/RL-r、APRI、FIB-4水平与肝纤维化发生的相关性[J]. 肝脏, 2024, 29(1): 68-72.
[3]	吴彬彬, 徐小琴, 顾星星, 解其华. 脂肪肝诊断中ElastPQ弹性成像技术检测肝硬度与肝纤维化评分及FIB-4指数的相关性分析[J]. 肝脏, 2024, 29(1): 73-76.
[4]	张维, 刘清林, 张慢, 安阳, 曹睦涵. sTfR、肝脾CT比值与老年非酒精性脂肪性肝病患者轻度认知功能障碍的相关性[J]. 肝脏, 2024, 29(1): 105-109.
[5]	陈璐, 杨妙芳, 汪芳裕. “口-肠-肝轴”在非酒精性脂肪性肝病中的作用[J]. 肝脏, 2024, 29(1): 110-113.
[6]	马驰, 杨涓, 郑盛. 肠道菌群与肝脏疾病研究进展[J]. 肝脏, 2024, 29(1): 113-116.
[7]	刘百怡, 饶慧瑛. 非酒精性脂肪性肝病更名及其影响[J]. 肝脏, 2023, 28(9): 1012-1014.
[8]	孔嘉宁, 施军平. 瘦型非酒精性脂肪性肝病的流行现状与自然转归[J]. 肝脏, 2023, 28(9): 1018-1019.
[9]	张思敏, 袁乙富, 吴小溪, 杜晟楠, 曹勤, 蒋元烨. 不同年龄非酒精性脂肪性肝病合并急性药物性肝损伤患者的临床特点分析[J]. 肝脏, 2023, 28(9): 1088-1092.
[10]	康碧莲, 刘天会. 脂蛋白脂肪酶与非酒精性脂肪性肝病[J]. 肝脏, 2023, 28(9): 1110-1111.
[11]	孙成林, 孙亚朦, 陈姝延, 尤红. 非酒精性脂肪性肝病无创评估的应用与前景[J]. 肝脏, 2023, 28(8): 889-891.
[12]	管炬博, 范建高. 非酒精性脂肪性肝病患者心血管疾病风险的研究进展[J]. 肝脏, 2023, 28(8): 892-893.
[13]	管炬博, 范建高. 非酒精性脂肪性肝病发病的脂肪组织功能障碍学说[J]. 肝脏, 2023, 28(7): 746-748.
[14]	邓朝华, 施军平. 孟德尔随机化分析在非酒精性脂肪性肝病危险因素研究中的应用[J]. 肝脏, 2023, 28(7): 749-750.
[15]	张思敏, 杜晟楠, 袁乙富, 何诗嘉, 曹勤, 蒋元烨. 瘦型非酒精性脂肪性肝病的临床特征及血清脂质组学研究[J]. 肝脏, 2023, 28(7): 799-805.